AstraZeneca will pay insitro $40 million upfront to apply AI to target discovery in MASH and cardiomyopathies, with no candidates named yet.
Feature|Articles|October 18, 2023
2023 Pharmaceutical Executive APEX Award Winners
Author(s)Mike Hollan
Advertisement
Pharmaceutical Executive is proud to present the winners of the 2023 Apex Awards. Judged by healthcare professionals across the US, the show recognizes companies and agencies for marketing campaigns that went above and beyond.
This year's show took place on October 17, 2023 at Gotham Hall in New York City.
The winners of the 2023 Apex awards are as follows:
Aesthetics/Dermatology
Branded (FDA Regulated)
- Company: Incyte Corporation
- Agency: Scientific Global Communications
Cardio Vascular
Disease Education/Awareness
- Company: Bristol Myers Squibb & Pfizer
- Agency: Heartbeat
Central Nervous System
Branded (FDA Regulated)
- Company: Supernus Pharmaceuticals
- Agency: CultHealth
Devices
Branded (FDA Regulated)
- Company: Viz.ai
- Agency: CrowdPharm
Devices
Disease Education and Awareness
- Company: Metame Health
- Agency: The Agency Network at MJH Life Sciences
Direct-to-Consumer
Disease Education and Awareness
- Company: AstraZeneca
- Agency: JPA Health
Direct-to-Consumer
Branded (FDA Regulated)
- Company: GSK
- Agency: Publicis
Direct-to-Patient
Branded (FDA Regulated)
Company: CISCRP
Agency: Praxis
Direct-to-Patient
Disease Education and Awareness
Company: GSK
Agency: Publicis
Hematology
Branded (FDA Regulated)
Company: Takeda
Agency: McCann
Immunology
Disease Education and Awareness
Company: UCB, Inc
Agency: Scientific Global Communications
Metabolic
Metabolic
Branded (FDA Regulated)
Company: Novo Nordisk
Agency: CultHealth
Metabolic
Disease Education and Awareness
Company: Bayer Pharmaceutical
Agency: Hill Holliday Health, an IPG Health Company
Oncology
Branded (FDA Regulated)
Company: Novartis Pharmaceuticals Corp.
Agency: Biolumina
Oncology
Disease Education and Awareness
- Company: Coherus Biosciences
- Agency: Confideo
Ophthalmology
Branded (FDA Regulated)
- Company: Thea Pharma Inc.
- Agency: Elevate Healthcare
Ophthalmology
Disease Education and Awareness
- Company: Tarsus Pharmaceuticals
- Agency: Heller Agency
Rare Disease
Branded (FDA Regulated)
- Company: Jazz Pharmaceuticals
- Agency: ConcentricLife
Rare Disease
Disease Education and Awareness
- Company: Travere Therapeutics
- Agency: Avalere Health
Women’s Health
Branded (FDA Regulated)
- Company: GSK
- Agency: Saatchi & Saatchi Wellness
Women’s Health
Disease Education and Awareness
- Company: Agile Therapeutics
- Agency: Heartbeat
Advertisement
Related to this article
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come first.
FDA is launching the Rare Disease Framework Initiative, aiming to tailor drug development and review requirements to the realities of small patient populations.
Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
Gilead and Vir Biotechnology Enter a $1.87 billion collaboration to discover three PRO-XTEN dual-masked T-cell engagers aimed at solid tumors.
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Advertisement
Advertisement
Trending on PharmExec
1
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
2
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
3
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
4
FDA Launches Rare Disease Framework Initiative
5